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A B S T R A C T
Background: There are limited data about Xpert-Ultra performance in different settings, in HIV-infected
persons, in those with a history of previous TB, and with trace readouts.
Methods: We evaluated the relative accuracy of Xpert-MTB/RIF and Xpert-Ultra in 272 selected but well-
characterized archived sputum samples. Of these, 168 were culture-positive (64/168 smear-positive and
104/168 smear-negative), and 104 were culture-negative (102/104 from patients with previous TB and 2/
104 from patients without a TB history). Assay-specific limit-of-detection (LOD) experiments were
conducted using serial dilutions of Mycobacterium tuberculosis H37Rv.
Results: Overall sensitivity (95%CI) in smear-negative culture-positive samples for Xpert-MTB/RIF and
Xpert-Ultra were 71.2% (62.5–79.9) and 77% (68.9–85.1), respectively (and in HIV-infected persons: 63.5%
(50–76.1) and 73.1% (61.1–85.2), respectively). The LOD for Xpert-Ultra was lower (9 versus 184 CFU/ml).
There were a total of 9/272 (3.3%) Xpert Ultra trace readouts (6/104 [5.8%]) in smear-negative culture-
positive persons, and 3/102 (3%) in culture-negative non-TB persons with a history of previous TB).
Conclusions: Xpert-Ultra had a lower LOD compared to Xpert-MTB/RIF. A small proportion of samples
(<5%) from culture-negative patients but with a history of previous TB had a likely false-positive trace
readout. These data inform the management of patients with suspected TB in endemic settings.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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The development of rapid and accurate diagnostic tests for
tuberculosis (TB), which decreases the time of treatment initiation,
is an important strategy to control the TB epidemic. The WHO
recommended Xpert MTB/RIF assay (Cepheid, USA) is an automat-
ed cartridge-based, real-time polymerase chain reaction (PCR) test
that has been proven to reduce time to treatment initiation in TB
patients (Boehme et al., 2011; Calligaro et al., 2017) by detecting
the presence of TB and drug resistance to rifampicin (RIFR) in
sputum samples within two hours (Theron et al., 2011). It has been* Corresponding author at: Lung Infection and Immunity Unit, Division of
Pulmonology and UCT Lung Institute, Dept. of Medicine, University of Cape Town,
South Africa.
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1201-9712/© 2020 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).shown to have better sensitivity (98%) at diagnosing TB over
sputum smear microscopy (20%–60%; Walusimbi et al., 2013).
However, it has suboptimal sensitivity in smear-negative sputum
(67%; (Walusimbi et al., 2013)), which is often the case in HIV-
infected patients (Theron et al., 2011). To improve the sensitivity,
Xpert Ultra was introduced, which has an enhanced assay design
and uses high-resolution melt analysis (Chakravorty et al., 2017).
The reported sensitivity for Xpert Ultra in smear-negative
sputum reached 78.9%, which is higher than Xpert MTB/RIF (66.1%)
(Chakravorty et al., 2017) and the assay performed better in
sputum from HIV-infected individuals (87.5% versus 68.6% for
Xpert Ultra versus Xpert MTB/RIF, respectively; Berhanu et al., 2018
). The threshold for detection with Xpert Ultra was 1-log CFU
better over Xpert MTB/RIF (12 CFU/ml versus 130 CFU/ml)
(Chakravorty et al., 2017). However, this improvement in
sensitivity comes at the cost of decreased specificity (Garcia-
Basteiro et al., 2017).ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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utility of Xpert Ultra in HIV-infected persons, in those with a
history of previous TB, and the epidemiology of trace readouts has
been poorly studied. It has been suggested that the latter may
represent true or false-positive results, and the optimal manage-
ment of such patients is unclear. There are also limited data about
the comparative limit of detection of the two Xpert assays.
Therefore, in the current study, we sought to evaluate the
diagnostic accuracy of Xpert MTB/RIF versus Xpert Ultra from
selected patients in a TB and HIV endemic setting and explore the
epidemiology of trace results.
Materials and methods
Case definitions
The following case definitions were used for the analysis:
(A) Confirmed active TB - patients fulfilled all of the following
criteria:
(i) Presented at the TB clinic with at least one WHO defined
symptom suggestive of TB.
(ii) Positive sputum culture for Mycobacterium tuberculosis (M.
tb).
(iii) Initiated on TB treatment.
(iv) Had resolution of their TB symptom(s) at 8 weeks of follow-
up.
(B) Confirmed non-TB - patients fulfilled all of the following
criteria:
(i) Presented at the TB clinic with at least one WHO defined
symptom suggestive of TB.
(ii) Negative sputum culture for M. tb.
(iii) Not Initiated on TB treatment.
(iv) Had resolution of their TB symptom(s) and/or who had a
confirmed alternative diagnosis at 8 weeks of follow-up.
(C) Previous TB - patients fulfilled all of the following criteria:
(i) Presented at the TB clinic with at least one (new-onset) WHO
defined symptom suggestive of TB.
(ii) Had a history of one or more episodes of culture or Xpert
confirmed TB.
(iii) Had completed TB treatment at least 6 months before their
current onset of symptoms.
Archived sputum samples
Sputum samples (n = 272) from symptomatic individuals
suspected of having pulmonary TB were obtained between June
2013 and December 2015 from TB clinics in Cape Town, South
Africa. The University of Cape Town Human Research Ethics
Committee approved (approval # 068/2016) the current study, and
all patients provided written informed consent for study
participation and biobanking of clinical samples for downstream
evaluation.
Xpert MTB/RIF and Xpert Ultra testing
The Xpert MTB/RIF and Xpert Ultra assays were performed as
described previously (Helb et al., 2010). Briefly, sodium hydroxide
and isopropanol-containing sample buffer (Cepheid, USA) was
added to the sputum sample at a ratio of 2:1 and incubated for 15
min at room temperature with gentle intermittent agitation.Following incubation, 2 ml of sample was transferred to the Xpert
MTB/RIF and/or Xpert Ultra cartridge and run on the Xpert system
(Cepheid, Dx System Version 4.0c), depending on the outcome
under investigation.
Limit-of-detection experiments
Sputum samples from culture and smear-negative patients
with no history of previous TB were combined, diluted in sample
buffer, and spiked with M. tb H37Rv at 1500, 750, 375, 188, 94, 47,
24, 12, 9, 5 and 0 CFUs/ml. Each dilution of spiked sputa was tested
using the Xpert MTB/RIF, and Xpert Ultra assay in triplicate, and the
results were compared at each concentration. Dilutions were
plated onto Middlebrook 7H9 agar (Sigma, Germany) containing
oleic albumin dextrose catalase (OADC) supplement (Becton
Dickinson, USA), and colony forming units (CFUs) were counted
to ensure that the spiked levels of CFU/ml were accurate.
The effect of serial freeze–thaw cycles on Xpert performance
Samples classified as smear-negative Xpert MTB/RIF-positive
and culture-positive (n = 16) were randomly selected from
biobanked samples to evaluate whether freeze–thawing the
sample has an effect on test performance. The samples underwent
three complete freeze–thaw cycles, after which Xpert MTB/RIF was
performed as described previously. The cyclic threshold (Ct) values
were compared to previously documented Xpert MTB/RIF results
using a fresh sample at the same time of sample collection.
Statistical analysis
For demographic analysis, the chi-squared (χ2) test was
employed for categorical variables; for continuous variables, the
Mann–Whitney test was used for non-parametrically distributed
data (GraphPad, Version 6). Diagnostic accuracy of Xpert MTB/RIF
and Xpert Ultra including, sensitivity and specificity, with or
without the trace call included for Xpert Ultra, was performed. The
Fishers Exact Test was utilized for comparison of the diagnostic
variables for Xpert MTB/RIF and Xpert Ultra. The diagnostic
accuracy analysis was performed in Stata, Version 13. A p-value of
<0.05 was considered significant for all statistical analyses.
Results
Patient clinical parameters and sputum sample characteristics
The demographic characteristics of the patients enrolled in the
study are shown in Table 1. Patient subgroups were pre-selected to
answer our research questions. Overall, the median age of the
patients was 39, with 60% (155/261) being males and 40% being
females (106/261).
The majority (62% 104/168) of patients in the confirmed
active-TB group were smear-negative (i.e., potentially with
paucibacillary disease) with 35% (58/168) of patients having
had a previous history of TB. The confirmed non-TB group almost
entirely [98% (102/104)] consisted of patients with a prior history
of tuberculosis with an HIV prevalence of 33% (31/93) in this group.
Xpert MTB/RIF and Xpert Ultra were positive for 82.1% and 82.7%,
respectively, amongst the confirmed active-TB patients.
Figure 1A shows the study plan of the patients tested for Xpert
MTB/RIF and Xpert Ultra (n = 272). Out of the 168 confirmed active-
TB cases, 64 and 104 were smear-positive and smear-negative,
respectively. For the confirmed active-TB, smear-negative sputum
samples, Xpert Ultra could detect five and three more TB cases than
Xpert MTB/RIF in the HIV-infected and HIV-uninfected patients,
respectively. Within the confirmed non-TB group with a history of
Figure 1. Study flow and LOD for Xpert MTB/RIF and Xpert Ultra. (A) Study flow showing the number of sputum samples analysed with Xpert MTB/RIF and Xpert Ultra.
#Fifteen samples had an unknown HIV status. *Two patients had no history of previous TB and two HIV results were of unknown status. p-Values compare the HIV-infected
versus uninfected status. (B) LOD for Xpert MTB/RIF and Xpert Ultra. Culture-negative, smear-negative pooled sputum samples were diluted 1:2 in lysis buffer. The diluted
sputum was spiked with M. tb H37Rv at 1500, 750, 375, 188, 94, 47, 24, 9, 5 and 0 CFUs/ml. Each dilution was analysed by Xpert MTB/RIF and Xpert Ultra in triplicate. The
shaded area indicates the relative CFU/ml where one or more of the replicates were either Xpert Ultra negative or trace. Xpert = Xpert MTB/RIF, Ultra = Xpert Ultra.
Table 1
Demographic characteristics of the sub-groups (data are n (%) unless otherwise stated).
Demographic data All samples (%) (n = 272) Confirmed active-TB (%) (n = 168) Non-TB (%) (n = 104) p-Value
Age
aMedian years (range) 39 (19–68) 39 (19–65) 39 (26–68)
Gender 0.1289
Male 164 (60.3) 94 (56) 70 (67.3)
Female 108 (39.7) 74 (44) 34 (32.7)
HIV-infected <0.0001
Yes 148 (54.4) 113 (67.2) 35 (33.7)
No 107 (39.3) 40 (23.8) 67 (64.4)
Not determined 17 (6.5) 15 (8.9) 2 (1.9)
CD4 count (cells/ml) (range)b 235 (6–788)C 235 (6–788)v 235 (25–681)w 0.1494
Smear status <0.0001
Smear-negative 191 (70.2) 104 (61.9) 87 (83.7)
Smear-positive 68 (25) 64 (38.1) 4 (3.8)
Unknown 13 (4.7) – 13 (12.5)
Previous TB <0.0001
Yes 160 (58.8) 58 (34.5) 100 (98.0)
<5 years ago 61 24 37
5  10 years ago 68 22 46
>10 years 56 14 42
No 111 (40.8) 109 (64.9) 2 (1.9)
Unknown 1 (0.4) 1 (0.6) –
Xpert MTB/RIF <0.0001
Positive 151 (55.5) 138 (82.1) 13 (12.5)
Negative 121 (44.5) 30 (17.9) 91 (87.5)
Xpert Ultra <0.0001
Positive 151 (55.5) 139 (82.7) 12 (11.5)
Negative 121 (44.5) 29 (17.3) 92 (88.5)
Trace 9/272 6/168 2.9 (3/104)
a Median (range).
b Performed if HIV-infected. There was no CD4 count data for 5C, 3v, and 2w patients, respectfully.
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TB cases above Xpert MTB/RIF in the HIV-infected patients and an
additional two in the HIV-uninfected patients.
Limit-of-detection (LOD) of Xpert MTB/RIF versus Xpert Ultra
The LOD for Xpert MTB/RIF and Xpert Ultra are shown in Figure
1B. Culture-negative, Xpert MTB/RIF-negative sputum samples
from individuals without a history of TB, and who did not receive
TB treatment with resolution of their respiratory symptoms onfollow-up, were pooled and diluted 2:1 (lysis buffer:sputum) in
lysis buffer as indicated in the materials and methods. The sputum
was spiked with 1500, 750, 375, 188, 94, 47, 24, 9, 5, and 0 CFUs/ml
of M. tb H37Rv and analyzed by Xpert MTB/RIF and Xpert Ultra. The
Xpert Ultra sputum samples spiked with 1500, and 750 CFU/ml had
similar average rpoB Ct values of approximately 28. Average rpoB Ct
values increased to approximately 29 when the Xpert Ultra sputum
samples were spiked with 187 CFU/ml. Xpert MTB/RIF could not
detect TB at a CFU/ml below 187, and Xpert Ultra was less
reproducible below 94 CFU/ml (Figure 1B), where one or more of
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Ultra was nine CFU/ml.
Sensitivity of Xpert MTB/RIF and Xpert Ultra in smear-negative
sputum samples from HIV-infected and HIV-uninfected patients with
definite TB
The sensitivity for Xpert MTB/RIF and Xpert Ultra for the HIV-
infected and HIV-uninfected sputum samples is shown in Table 2.
Overall the sensitivity for Xpert MTB/RIF and Xpert Ultra was 71.2%
(95% CI; 62.5%–79.9%) and 77% (68.9%–85.1%), respectively. For the
sputum samples from the HIV-infected individuals, the sensitivity
for Xpert MTB/RIF was lower at 63.5% (50%–76.1%) compared to
that of Xpert Ultra (73.1% [61.1%–85.2%]; Table 2); however, this
was not significant. The sensitivity for Xpert MTB/RIF and Xpert
Ultra was 73% (58.7%–87.3%) and 78.4% (65.1%–91.7%), respectively,
for the sputum samples from HIV-uninfected individuals.
Accuracy of Xpert MTB/RIF and Xpert Ultra in sputum samples from
non-TB patients with previous history of TB (false positivity rate)
The diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for
non-TB patients with previous history of TB is shown in Table 3.
The sensitivity for Xpert MTB/RIF and Xpert Ultra were 12.7% [7%–
20.8%; p = 0.470] and 11.8% [6.2%–19.6%], respectively. In the HIV-
infected individuals versus the HIV-uninfected individuals the
sensitivity of Xpert MTB/RIF was 11.4% [3.2%–26.7%] versus 13.8%
[6.5%–24.7%]; p = 0.732), respectively and Xpert Ultra was 17.1%
[6.6%–33.6%] versus 9.2% [3.5%–19%; p = 0.246], respectively.
The significance of Xpert Ultra trace readouts
In the smear-negative active TB group (Table 2)
When the trace results for Xpert Ultra were excluded from the
analysis, the sensitivity did not change for both the HIV-infected
group (63.5% [49%–76.4%] and the HIV-uninfected groups (75.7%
[58.8%–88.2%]) (Table 2). The Xpert Ultra trace readouts appeared
higher in the HIV-infected (9.6% [3.2%–21%]; p = 0.199) versus the
HIV-uninfected individuals (2.7% [0%–14.2%]), but this was not
significant.Table 2
Sensitivity of Xpert MTB/RIF and Xpert Ultra in smear-negative culture-positive sampl
Confirmed smear-negative TB (n = 1
Overall (n = 104) 
Positive 
(%, 95%CI, n/N, p-value) 
Xpert MTB/RIF 71.2%, 
62.5%–79.9%, 
74/104 
Xpert Ultra (with trace) 77%, 
68.9%–85.1%, 
80/104, 
p = 0.343 
Xpert Ultra (without trace) 71.2%, 
61.4%–79.6%, 
74/104, 
p = 0.484 
Xpert Ultra (trace readout) 5.8% 
2.1%–12.1% 
6/104 
a Fifteen patients had an unknow HIV status.
* P values are for comparison between Xpert MTB/RIF and Xpert Ultra.
** P values are for comparison between HIV-infected and uninfected.In the non-TB group with a previous history of TB (Table 3)
When the trace results were excluded for Xpert Ultra, the
sensitivity in the HIV-infected versus the HIV-uninfected individ-
uals was similar at 11.4% (3.2%–26.7%; p = 0.534) and 7.7% (2.5%–
17%), respectively.
Positive predictive values (PPV) and negative predictive values (NPV)
of Xpert MTB/RIF and Xpert Ultra overall and when stratified to HIV-
infected and smear-negative samples
The PPV and NPV values for the study cohort overall and when
stratified according to HIV-infected and smear-negative sputum
samples is shown in Figure S1 (Supplementary material). Overall
the PPV and NPV did not change for Xpert MTB/RIF versus Xpert
Ultra (91.4% [55.9%–89.3%] vs. 92.1% [77.4%–100%] and 75.2%
[60.6%–92.3%] vs. 76% [61.3%–93.3%], respectively). When stratified
to HIV-infected sputum samples, the NPV appeared to decrease for
both Xpert MTB/RIF (75.2% [60.6%–92.3%] vs. 62% [42.1%–88%]) and
Xpert Ultra (76% [61.3%–93.3%] vs. 61.7% [41.3%–88.6%]), but this
was not significant. The PPV and NPV did not change for both tests
overall compared to smear-negative sputum samples.
The effect of freeze–thaw cycles on the performance of Xpert MTB/RIF
The effect of freeze/thawing sputum samples on Xpert MTB/RIF
performance is shown in Figure 2. Eight pairs of culture-positive,
Xpert MTB-RIF-positive sputum samples were randomized and
either remained fresh or were subjected to three freeze/thaw
cycles before performing Xpert MTB/RIF. On average, the Ct values
for the freeze/thawed sputum samples (Ct = 23; p = 0.078) were
similar to the fresh sputum samples (Ct = 26), indicating that
freeze/thawing sputum samples does not affect Xpert MTB/RIF
performance (Figure 2).
Distribution of test-positive results for culture, Xpert MTB/RIF, and
Xpert Ultra
The relationship between test positivity for culture, Xpert MTB/
RIF, and Xpert Ultra is shown in Figure 3. Culture could detect TB in
an additional 19 sputum samples above Xpert MTB/RIF and Xpertes stratified according to HIV status.
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False-positive rates (specificity) of Xpert MTB/RIF and Xpert Ultra for the detection of TB in sputum samples from non-TB patients with a previous history of TB.
Non-TB with history of previous TB (n = 102a)
Overall (n = 102) HIV infected (n = 35) HIV uninfected (n = 65)
Positive Positive Positive
(%, 95%CI, n/N, p-value) (%, 95%CI, n/N, p-value) (%, 95%CI, n/N, p-value)




Xpert Ultra (with trace) 11.8%, 17.1% 9.2%
6.2%–19.6%, 6.6%–33.6% 3.5%–19%
12/102, 6/35 6/65
p = 0.470 *p = 0.495 *p = 0.410
**p = 0.246
Xpert Ultra (without trace) 8.8%, 11.4% 7.7%
4.1%–16.1%, 3.2%–26.7% 2.5%–17%
9/102, 4/35 5/65
p = 0.70 *p = 0.258
**p = 0.534
a Two patients had an unknow HIV status.
* P values are for comparison between Xpert MTB/RIF and Xpert Ultra.
** P values are for comparison between HIV status.
Figure 2. Ct values of fresh or freeze–thawed (3 cycles) sputum samples (16
sputum samples; 8 pairs of samples). Smear-negative culture-positive Xpert MTB/
RIF-positive sputum samples were subjected to three rounds of freeze/thaw prior to
repeat Xpert MTB/RIF. The dotted line represents the median Ct value = 27.
Figure 3. Venn diagram showing the relationship between test positivity for Xpert
MTB/RIF (n = 145), Xpert Ultra (n = 151), and culture (n = 168).
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detecting TB in an additional six and five sputum samples,
respectively.
Discussion
We evaluated the diagnostic accuracy of Xpert MTB/RIF and
Xpert Ultra using selected archived sputum samples from patients
with suspected TB in a high TB and HIV prevalence setting. The
three key findings in our study were: (1) Xpert Ultra had lower LOD
for M. tb compared to Xpert MTB/RIF, (2) trace results with Xpert
Ultra were relatively infrequent even in the group of patients who
have a predisposition for trace false positive readouts (i.e., non-TB
with a previous history of TB who turned out to be culture-negative
and remained well on follow-up), Xpert Ultra positivity was 3%,
(3) Xpert Ultra sensitivity was consistently lower in HIV-infected
persons and trace readouts were higher in this group, and (4)
overall, Xpert Ultra was 6% more sensitive than Xpert MTB/RIF insmear-negative samples, although this did not reach statistical
significance.
Overall, a minority of samples (3%) constituted trace readouts.
This was less than the 10% overall trace readout found by Berhanu
et al. in South Africa (Berhanu et al., 2018) . In that study,
reclassification of trace results resulted in a loss of sensitivity of
5.6% in the smear-negative group (Berhanu et al., 2018). In the
study by Dorman et al., the reduction in sensitivity from excluding
the trace readout was almost 9% in smear-negative culture-
positive persons (Dorman et al., 2018). In our study, this figure was
less than 6% in the smear-negative group, though this increased to
almost 10% in HIV-infected persons. This may be due to several
factors, including using a convenience sample set, patient
classification based on follow-up, differential disease burden,
and different TB strains. The interpretation of trace readouts on the
Xpert Ultra semi-quantitative scale is controversial.
On the one hand, it may represent a true positive, i.e., detection
of M. tb DNA, where the culture result is falsely negative. This could
be due to a variety of factors including sub-clinical TB, differentially
culturable mycobacteria that do not optimally grow on conven-
tional culture media (Motyl et al.,1990), sampling error (sequential
paired samples collected in the field are known to be discordant
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falsely culture-negative due to sample preparation, death of
mycobacteria during transport to the laboratory, or overgrowth of
mouth flora. Indeed, in the Dorman study, longer-term follow-up
uncovered Xpert Ultra-positive culture-negative patients who
subsequently turned out to be culture-positive (Dorman et al.,
2018). In the Berhanu report, some samples became culture-
positive well beyond the 42-day culture threshold limit (Berhanu
et al., 2018). On the other hand, trace readouts may be falsely
positive due to technical factors including detection of DNA
artifacts (e.g., primer dimers) and inherent noise at the limit of
detection of the fluorescence signal (false positive signal at very
low-level fluorescence). A drawback of our study was that we did
not sequence the amplicons from the Xpert Ultra cartridges, which
could inform on the issue of technical artifacts. Dorman et al.
sequenced amplicons obtained from 14 cartridges (samples from
14 participants that were Xpert Ultra-positive but culture-
negative); in 12 of the 14 participants detection of M. tb DNA
was confirmed (Dorman et al., 2018).
How trace readouts should be handled in clinical practice
remains unclear, and there are implications for missing a TB
diagnosis versus erroneously prescribing potentially toxic treat-
ment. The current WHO guidelines suggest that trace readouts
should signal TB treatment in paucibacillary disease (e.g., HIV co-
infection, extra-pulmonary TB, etc.), while in other contexts, repeat
testing should be performed. However, this may not be feasible in
an endemic setting where almost 10% of readouts are trace
(Dorman et al., 2018). A prior modeling study has shown that Xpert
Ultra, despite lower specificity (but higher sensitivity), could have
a mortality benefit in TB and HIV hyper-endemic settings. At the
same time, over-treatment of false-positive cases will likely occur
in low prevalence regions (Kendall et al., 2017).
Our study highlights that trace-positive results in those with a
previous history of TB should be carefully considered before TB
treatment is commenced. Prospective studies in patients with
trace readouts will be required to provide more guidance on how to
optimally manage such patients in different clinical settings.
However, we also quantified the magnitude of trace readouts in
those who were culture-negative but with a prior history of TB. Our
cohort was particularly well-characterized, and, in such patients,
we had a follow-up of at least two months with a resolution of
symptoms suggesting that Xpert Ultra in this context was
detecting ‘old’ residual DNA from a prior episode. Indeed, detection
of DNA in patients with previous TB is well-described, and Xpert
Ultra cannot distinguish between the DNA from viable organisms
and those that have demised (Theron et al., 2016; Theron et al.,
2018). We also saw the well-described phenomenon of improved
sensitivity with a trace readout but reduced specificity as outlined
by others (Berhanu et al., 2018; Dorman et al., 2018). In our study,
trace readouts occurred mostly in patients with a history of TB
treatment within two years of their most recent TB episode. In this
group of patients, analyzing the data by re-classifying trace calls as
“negative” improves the specificity from 62% to 77%.
There is little data about Xpert Ultra’s performance in HIV-
infected persons, including those with a previous history of TB.
Our results suggest that Xpert Ultra sensitivity (irrespective of
the version) was lower in HIV-infected participants than HIV-
uninfected participants, probably related to the more pauciba-
cillary nature of the disease (at least in sputum samples) in such
patients. The contribution of trace readouts to improving
sensitivity was higher in HIV-infected than uninfected persons.
Given the low burden of mycobacteria in the sputum of HIV-
infected patients, the higher mortality seen in such patients, and
inherent difficulties in diagnosis, the WHO has recommended
that trace readouts in such patients should signal initiation of TB
treatment. Our data showed that a history of previous TB hadminimal impact on HIV-infected compared to uninfected
persons.
There are limited data comparing performance between Xpert
Ultra and Xpert MTB/RIF (Berhanu et al., 2018; Dorman et al., 2018).
Overall, though our limited sample sizes did not reach significance,
we did confirm the higher sensitivity of Xpert Ultra compared to
Xpert MTB/RIF. Also, we provide laboratory evidence that Xpert
Ultra performed better in in vitro studies using serial dilutions of M.
tb. This is concordant with the findings of Chakravorty et al. (LOD
for Xpert Ultra was 15.6 CFU/ml versus 112.6 CFU/ml for Xpert
MTB/RIF) (Chakravorty et al., 2017). An interesting finding is that
there were also individuals that were Xpert MTB/RIF cartridge
positive but Xpert Ultra negative. This probably represents
sampling error, and discordance between sequentially obtained
samples is well recognized (Chakravorty et al., 2017).
Our study has several limitations. First, the small sample sizes
limited our power to make intergroup sensitivity and specificity
comparisons. However, we were limited by the size of our biobank,
and our principal aim was to perform a preliminary interrogation
of trace readouts and to gain more information about performance
in HIV-infected persons. Second, we used biobanked rather than
fresh samples, which may have impacted our results. However,
similar trends and results were shown in the Berhanu, and Dorman
reports. We also undertook experiments showing that freeze–thaw
probably had a negligible effect on the study findings (though
again sample sizes were limited and, if anything, freeze–thaw
improved performance). Third, we did not perform sequencing of
the cartridge amplicons. However, we were limited by resource
constraints; this would have enabled us to consolidate technical
false-positives but would have not corrected misclassification bias
in those with previous TB. Fourth, the lower than predicted
proportion of trace readouts compared to previous reports (
Berhanu et al., 2018; Dorman et al., 2018) may have been due to
suboptimal sample volume in some of the samples (not strictly
recorded before running the Ultra assay) (Ho et al., 2015; Zimba
et al., 2019) through our biobanking protocols stipulated collection
of at least a one ml volume of sputum.
In conclusion, Xpert Ultra had a lower limit of detection
compared to Xpert MTB/RIF. Moreover, we confirmed that a
significant minority of samples (<5%) comprised trace readouts,
and this may represent a false-positive signal in those with
previous TB. Prospective studies are required on how to optimally
manage such patients.
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